[Form 4] CRYO CELL INTERNATIONAL INC Insider Trading Activity
Rhea-AI Filing Summary
Cryo-Cell International disclosed new equity awards to its VP Finance and CFO, Jill M. Taymans. On January 7, 2026, she received two stock option grants at an exercise price of $3.54 per share. One grant covers 10,000 options that vest one-third on the grant date, one-third on January 7, 2027, and one-third on January 7, 2028. The second grant covers 20,000 options under the Cryo-Cell 2022 Stock Incentive Plan, split into three equal tranches that each require both time-based vesting and the stock reaching average closing prices of at least $6, $8, and $10 per share over 20 consecutive trading days, tied to the first, second, and third anniversaries of the grant. Taymans also reports 45,396 shares of common stock owned directly and multiple prior option awards with expirations ranging from 2026 to 2031.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 10,000 | $3.54 | $35K |
| Grant/Award | Stock Option | 20,000 | $3.54 | $71K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Stock options vest 1/5 per year commencing on September 23, 2020. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027. Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.
FAQ
Who is the insider in the 2026 Form 4 for CCEL and what is their role?
The Form 4 reports transactions by Jill M. Taymans, who serves as VP Finance and Chief Financial Officer of Cryo-Cell International Inc. She is an officer but not listed as a director or 10% owner.
What new stock options did Cryo-Cell CFO Jill Taymans receive on January 7, 2026?
On January 7, 2026, Jill Taymans received two stock option awards. One is for 10,000 options at an exercise price of $3.54 per share. The other is for 20,000 options, also at $3.54 per share, granted under the Cryo-Cell 2022 Stock Incentive Plan.
How do the time-based vesting terms work for Jill Taymans’ January 7, 2026 Cryo-Cell options?
For the 10,000-option grant dated January 7, 2026, the options vest one-third upon issuance, one-third on January 7, 2027, and one-third on January 7, 2028, subject to her continued service.
What performance conditions apply to the 20,000 Cryo-Cell options granted to the CFO?
The 20,000-option grant is split into three equal tranches. One tranche vests after the first anniversary and requires the stock to achieve an average closing price of at least $6 over 20 consecutive trading days. The second tranche uses an $8 price level after the second anniversary, and the third tranche uses a $10 level after the third anniversary, in each case requiring continued service.
What other stock option holdings does the Cryo-Cell CFO report in this Form 4?
Jill Taymans reports several existing stock option positions held directly, including 7,500 options at $3.10 expiring on June 2, 2026, 7,000 options at $8.00 expiring on September 23, 2027, 20,000 options at $4.62 expiring on January 13, 2028, 10,000 options at $5.88 expiring on December 22, 2028, and 10,000 options at $7.35 expiring on January 21, 2030, along with the new grants expiring on January 7, 2031.
Are the January 7, 2026 Cryo-Cell stock option grants to the CFO direct or indirect holdings?
The Form 4 lists all of Jill Taymans’ reported stock option grants, including those dated January 7, 2026, as held with direct (D) ownership, with no separate entity or indirect ownership structure disclosed.